Welcome to our dedicated page for Sera Prognostics SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Sera Prognostics, Inc. (NASDAQ: SERA), a Salt Lake City–based health diagnostics company focused on precision pregnancy care and preterm birth risk prediction. As a public company, Sera files annual, quarterly, and current reports that describe its financial condition, operations, and key clinical and commercial developments.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of Sera’s business, including its focus on the PreTRM® Test, a blood-based biomarker test for individualized risk prediction of spontaneous preterm birth in asymptomatic singleton pregnancies. These filings typically include information on revenues, operating expenses, research and development activities, and risk factors relevant to the company’s diagnostics business.
Current reports on Form 8-K document material events such as the release of quarterly financial results and significant clinical milestones. Recent 8-K filings reference press releases announcing second and third quarter financial results and the acceptance of the PRIME study for publication in a peer-reviewed journal. These filings help readers track how clinical evidence, such as the PRIME randomized controlled trial, connects to Sera’s commercial and strategic plans.
Users can also monitor Form 4 and other insider transaction filings, when available, to see reported trades by directors, officers, or significant shareholders. Stock Titan’s tools surface new SERA filings as they appear in the SEC’s EDGAR system and provide AI-powered summaries to explain key points, highlight important sections in lengthy documents, and make it easier to understand how disclosures about the PreTRM Test, payer engagement, and financial performance may relate to the company’s overall trajectory.
Sera Prognostics, Inc. filed a current report to share that findings from its Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs (“PRIME”) study have been accepted for publication in a peer-reviewed journal. The company disclosed this information under a Regulation FD disclosure, indicating it was also announced in a press release dated November 24, 2025, furnished as an exhibit to the report.
Sera Prognostics (SERA) filed its Q3 2025 report, highlighting modest revenue and a continued focus on funding and operations. Revenue was $16 thousand for the quarter and $71 thousand year-to-date. The company reported a Q3 net loss of $7.8 million and a year-to-date net loss of $24.0 million, driven by operating expenses of $9.0 million in the quarter.
Liquidity strengthened earlier in the year from a February 2025 underwritten offering, delivering $53.6 million in net proceeds. As of September 30, 2025, cash, cash equivalents and marketable securities totaled $102.4 million, with total assets of $108.1 million and stockholders’ equity of $82.2 million. Operating cash used year-to-date was $19.5 million. Deferred revenue stood at $20.3 million, reflecting contractual arrangements to be recognized upon delivery of test results. The company amended and extended its headquarters lease in September 2025, with a noncurrent operating lease obligation of $2.4 million.
Sera Prognostics, Inc. furnished an 8‑K announcing financial results for the third quarter ended September 30, 2025. The company disclosed the results and business highlights via a press release furnished as Exhibit 99.1.
The information under Item 2.02, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act, and is not incorporated by reference except as expressly stated.
Sera Prognostics (SERA) reported an insider transaction by its Chief Executive Officer and Director. On 11/10/2025, the reporting person sold 11,594 shares of Class A common stock at a weighted average price of $2.62. The filing states the sale was executed to cover tax withholding obligations tied to the vesting of RSUs and was not a discretionary trade. The shares were sold via a block trade within a price range of $2.30–$3.04. Following the transaction, the insider beneficially owns 796,296 shares.
Sera Prognostics (SERA) insider transaction: the company’s Chief Data Officer reported a sell-to-cover trade tied to RSU vesting. On 11/10/2025, 7,073 shares of Class A common stock were sold to satisfy tax withholding, a non-discretionary transaction under the issuer’s “sell to cover” election.
The sale executed at a $2.62 weighted average price within a $2.30–$2.62 range. Following the transaction, the reporting person beneficially owns 168,596 shares, held directly.
Sera Prognostics (SERA): Form 4 insider transaction. The company’s General Counsel reported the sale of 7,059 shares of Class A common stock on 11/10/2025 at a weighted average price of $2.62. The filing states the shares were sold to satisfy tax withholding obligations tied to RSU vesting under a mandated “sell to cover,” indicating it was not a discretionary trade. Following the transaction, the insider directly beneficially owns 119,758 shares. The sale was executed as a block trade with prices ranging from $2.30 to $3.04.
Sera Prognostics (SERA) reported an insider transaction by its Chief Information Officer. On 11/10/2025, the officer sold 6,528 Class A common shares in a mandated “sell to cover” to satisfy tax withholding triggered by RSU vesting. The transaction is noted as non‑discretionary under the company’s election.
The shares were sold at a weighted average price of $2.62, with individual trades ranging from $2.30 to $3.04. Following the transaction, the reporting person beneficially owns 89,404 shares, held directly.
Sera Prognostics (SERA) insider transaction: the company’s Chief Scientific Officer reported a sale of 7,767 shares of Class A common stock on 11/10/2025 at a weighted average price of $2.62. The filing states the sale was made to cover tax withholding upon RSU vesting under a mandated “sell to cover” arrangement.
Following the transaction, the reporting person beneficially owned 151,726 shares, held directly. The block trade occurred across prices ranging from $2.30 to $3.04.
Sera Prognostics (SERA) disclosed an insider transaction by its Chief Financial Officer. On 11/10/2025, the officer sold 6,351 shares of Class A common stock at a weighted average price of $2.62 to cover tax withholding tied to RSU vesting, as required by the issuer’s sell-to-cover policy. The block trade occurred across multiple transactions priced between $2.30 and $3.04. After the sale, the officer beneficially owns 278,319 shares, held directly.
Sera Prognostics (SERA) filed a Form 4 reporting a routine sell-to-cover. On 11/05/2025, a director sold 221 shares of Class A common stock at a $3.04 weighted average price to satisfy tax withholding from vested RSUs. The filing notes the sale was mandated by the issuer’s “sell to cover” election and was not a discretionary trade by the insider. Following the transaction, the reporting person beneficially owns 58,032 shares, held directly. The shares were sold in multiple trades between $3.03 and $3.05.